HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arnold, T. M. Articles by Messmer, K. J. Search for Related Content PubMed PubMed Citation Articles by Arnold, T. M. Articles by Messmer, K. J.

TAMRAM. ARNOLD, PHARM.D., BCPS, is Clinical Pharmacy Specialist, Richard L. Roudebush Veterans Affairs Medical Center (VAMC), Indianapolis, IN. GRAEMEN. FORREST, M.D., M.B.B.S., is Assistant Professor, School of Medicine, University of Maryland, Baltimore, and Assistant Director, Infectious Diseases, Greenbaum Cancer Center, Baltimore. KARENJ. MESSMER, PHARM.D., is Clinical Pharmacy Specialist, Richard L. Roudebush VAMC.

Address correspondence to Dr. Arnold at the Richard L. Roudebush Veterans Affairs Medical Center, 1481 West 10th Street, Indianapolis, IN 46202 (tamra.arnold{at}va.gov).

Purpose. The role of polymyxin antibiotics in the treatment of multidrug-resistant gram-negative infections is reviewed. Summary. Antimicrobial resistance is an increasing problem across hospitals worldwide, especially in intensive care settings, where nosocomial infections are 5–10 times more likely to occur than on the general wards. The polymyxins, a group of basic polypeptide antibiotics, were first isolated from Bacillus species in the late 1940s and appear to have a surface detergent effect, making them active against most gram-negative organisms. Early clinical reports suggested a high rate of toxicity associated with the polymyxins, specifically nephrotoxicity (20%) and neurotoxicity (7%); thus the polymyxins had largely fallen out of favor. However, recent studies have suggested that the toxicities associated with the polymyxins may be less severe and less frequent than earlier reports. The emergence of multidrug-resistant gram-negative organisms has led to a reemergence in the use of this antibiotic class. Various clinical trials that evaluated the polymyxins for the treatment of multidrug-resistant gram-negative organisms found that these antibiotics have acceptable effectiveness and may be used if necessary. Conclusion. The polymyxins have become a last resort for the treatment of infections caused by multidrug-resistant gram-negative organisms. Recent studies have suggested that the frequency of polymyxin-associated nephrotoxicity and neurotoxicity may not be as high as was once thought. The polymyxins seem to be effective in treating various infections caused by multidrug-resistant gram-negative organisms but should not be used as first-line therapy until more is known about this class of antibiotics. Index terms: Antibiotics; Drug use; Gram-negative bacterial infections; Hospitals; Polymyxin; Rational therapy; Resistance; Toxicity

 

This article has been cited by other articles:

				G. N. Forrest and K. Tamura Rifampin Combination Therapy for Nonmycobacterial Infections Clin. Microbiol. Rev., January 1, 2010; 23(1): 14 - 34. [Abstract] [Full Text] [PDF]

				K. Barrow and D. H. Kwon Alterations in Two-Component Regulatory Systems of phoPQ and pmrAB Are Associated with Polymyxin B Resistance in Clinical Isolates of Pseudomonas aeruginosa Antimicrob. Agents Chemother., December 1, 2009; 53(12): 5150 - 5154. [Abstract] [Full Text] [PDF]

				T. Mogi, Y. Murase, M. Mori, K. Shiomi, S. Omura, M. P. Paranagama, and K. Kita Polymyxin B Identified as an Inhibitor of Alternative NADH Dehydrogenase and Malate: Quinone Oxidoreductase from the Gram-positive Bacterium Mycobacterium smegmatis J. Biochem., October 1, 2009; 146(4): 491 - 499. [Abstract] [Full Text] [PDF]

				L. Weinstein, T.-L. Doan, and M. A. Smith Neurotoxicity in patients treated with intravenous polymyxin B: Two case reports Am. J. Health Syst. Pharm., February 15, 2009; 66(4): 345 - 347. [Abstract] [Full Text] [PDF]